



UPDATE ON STATUS OF FIRB APPROVAL

13 November 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (**Mayne Pharma**) refers to its proposed acquisition by Cosette Pharmaceuticals, Inc. (**Cosette**) by way of scheme of arrangement (**Scheme**).

This afternoon, Mayne Pharma was notified that the Foreign Investment Review Board (**FIRB**) had unilaterally extended the statutory deadline for FIRB approval to 17 November 2025.

The Scheme remains subject to FIRB approval, Court approval and other conditions as set out in the Scheme Booklet (and as outlined in clause 3.1 of the Scheme Implementation Deed). If these conditions are satisfied, the indicative timetable for the Scheme announced to the market on 7 November 2025 remains the same. Mayne Pharma will update the market if there is any need to amend the indicative timetable, including the date for the Second Court Hearing.

Mayne Pharma Shareholders do not need to take any action at this time.

- ENDS -

Authorised for release to the ASX by the Board Chair

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.